BR0314980A - Inibidores de hidrolase de amida de ácido graxo - Google Patents

Inibidores de hidrolase de amida de ácido graxo

Info

Publication number
BR0314980A
BR0314980A BR0314980-3A BR0314980A BR0314980A BR 0314980 A BR0314980 A BR 0314980A BR 0314980 A BR0314980 A BR 0314980A BR 0314980 A BR0314980 A BR 0314980A
Authority
BR
Brazil
Prior art keywords
fatty acid
acid amide
faah
amide hydrolase
competitive inhibitors
Prior art date
Application number
BR0314980-3A
Other languages
English (en)
Inventor
Dale L Boger
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR0314980A publication Critical patent/BR0314980A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"INIBIDORES DE HIDROLASE DE AMIDA DE áCIDO GRAXO". A presente invenção refere-se a Inibidores competitivos aperfeiçoados de FAAH empregam um <244>-ceto farmacóforo heterocíclico e uma subunidade de ligação tendo uma insaturação <sym>. O <244>-ceto farmacóforo heterocíclico e uma unidade de ligação são ligados um ao outro, de preferência por uma cadeia hidrocarboneto. O aperfeiçoamento reside no uso de um farmacóforo heterocíclico selecionado de oxazóis, oxadiazóis, tiazóis e tiadiazóis que têm substituintes alquila ou arila em suas posições 4 e/ou 5. Os inibidores competitivos aperfeiçoados de FAAH apresentam atividade aumentada em relação aos inibidores competitivos convencionais de FAAH.
BR0314980-3A 2002-10-08 2003-10-08 Inibidores de hidrolase de amida de ácido graxo BR0314980A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41724702P 2002-10-08 2002-10-08
PCT/US2003/031975 WO2004033652A2 (en) 2002-10-08 2003-10-08 Inhibitors of fatty acid amide hydrolase

Publications (1)

Publication Number Publication Date
BR0314980A true BR0314980A (pt) 2005-08-09

Family

ID=32093990

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314980-3A BR0314980A (pt) 2002-10-08 2003-10-08 Inibidores de hidrolase de amida de ácido graxo

Country Status (15)

Country Link
US (1) US7662971B2 (pt)
EP (2) EP2093220A3 (pt)
JP (1) JP4628789B2 (pt)
KR (1) KR20050070041A (pt)
CN (1) CN1703407A (pt)
AT (1) ATE431342T1 (pt)
AU (1) AU2003275493A1 (pt)
BR (1) BR0314980A (pt)
CA (1) CA2501575A1 (pt)
DE (1) DE60327640D1 (pt)
EA (1) EA008767B1 (pt)
ES (1) ES2325686T3 (pt)
MX (1) MXPA05003762A (pt)
WO (1) WO2004033652A2 (pt)
ZA (1) ZA200501837B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
BR0314980A (pt) 2002-10-08 2005-08-09 Scripps Research Inst Inibidores de hidrolase de amida de ácido graxo
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
DE102004039326A1 (de) * 2004-08-12 2006-02-16 Abbott Gmbh & Co. Kg Neue medizinische Verwendungen und Verfahren
US7351724B2 (en) 2004-10-15 2008-04-01 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
EP1954137A4 (en) 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
JP2009527483A (ja) 2006-02-17 2009-07-30 ザ・スクリプス・リサーチ・インステイチユート 脂肪酸アミドヒドロラーゼの調節因子としてのオキサゾールケトン
WO2008013963A2 (en) 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
WO2008030532A2 (en) * 2006-09-08 2008-03-13 The Scripps Research Institute Substituted oxazole ketone modulators of fatty acid amide hydrolase
AU2008257154B2 (en) * 2007-05-25 2014-03-06 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
EP2161997A4 (en) * 2007-05-31 2011-04-06 Scripps Research Inst TRICYCLIC INHIBITORS OF FATTY ACID AMIDHYDROLASE
CA2714743C (en) * 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US20110184026A1 (en) * 2008-06-19 2011-07-28 Boger Dale L C4-substituted alpha-keto oxazoles
WO2010005572A2 (en) * 2008-07-09 2010-01-14 The Scripps Research Institute Alpha-keto heterocycles as faah inhibitors
EP2321288B1 (en) 2008-08-04 2014-03-19 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of faah
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP5657566B2 (ja) * 2008-12-24 2015-01-21 バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． 医薬品
AR076687A1 (es) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
ES2626246T3 (es) 2009-09-09 2017-07-24 Sumitomo Dainippon Pharma Co., Ltd. Derivado de 8-oxodihidropurina
CA2782797C (en) 2009-10-02 2018-08-07 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
US20120225097A1 (en) 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
BR112012018913A2 (pt) * 2010-01-28 2017-06-20 Merck Sharp & Dohme "composição farmacêutica, e, uso da composição"
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
US9006433B2 (en) 2010-04-21 2015-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
ES2888231T3 (es) * 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
CN102964311B (zh) * 2011-09-01 2016-03-09 大丰海嘉诺药业有限公司 一种合成4-甲基-5-烷氧基噁唑的方法
ES2648188T3 (es) * 2012-02-17 2017-12-29 Epitech Group S.P.A. Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
WO2015066277A1 (en) 2013-11-01 2015-05-07 Merial Limited Antiparisitic and pesticidal isoxazoline compounds
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US20160244860A1 (en) * 2015-02-20 2016-08-25 Cytec Industries Inc. Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP3095787A1 (en) * 2015-05-22 2016-11-23 Universiteit Leiden Pharmaceutically active compounds as dag-lipase inhibitors
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
JP7531351B2 (ja) 2019-11-13 2024-08-09 東京エレクトロン株式会社 基板処理方法、基板処理装置、および基板処理システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA19269A1 (fr) * 1980-09-16 1982-04-01 Lilly Co Eli Perfectionnement relatif a des derives de n-arylbenzamides .
US5646289A (en) * 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
BR0314980A (pt) 2002-10-08 2005-08-09 Scripps Research Inst Inibidores de hidrolase de amida de ácido graxo

Also Published As

Publication number Publication date
US20060111359A1 (en) 2006-05-25
ES2325686T3 (es) 2009-09-14
AU2003275493A1 (en) 2004-05-04
MXPA05003762A (es) 2005-07-22
ATE431342T1 (de) 2009-05-15
EA200500633A1 (ru) 2005-10-27
EP2093220A3 (en) 2009-11-11
ZA200501837B (en) 2006-06-28
DE60327640D1 (pt) 2009-06-25
WO2004033652A2 (en) 2004-04-22
CA2501575A1 (en) 2004-04-22
WO2004033652A3 (en) 2004-09-16
EA008767B1 (ru) 2007-08-31
EP2093220A2 (en) 2009-08-26
JP2006502229A (ja) 2006-01-19
US7662971B2 (en) 2010-02-16
KR20050070041A (ko) 2005-07-05
EP1549624A4 (en) 2006-09-20
CN1703407A (zh) 2005-11-30
JP4628789B2 (ja) 2011-02-09
EP1549624A2 (en) 2005-07-06
EP1549624B1 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
BR0314980A (pt) Inibidores de hidrolase de amida de ácido graxo
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
NO20064418L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner
WO2004018465A3 (en) Benzonaphthyridines with pde 3/4 inhibiting activity
HUP0303037A2 (hu) Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények
BR0307060A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
ATE435219T1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
PL2937341T3 (pl) Pochodne fenyloamidowe kwasu 4-(benzylo)-piperazyno-1-karboksylowego oraz związki powiązane, jako modulatory hydrolazy amidu kwasu tłuszczowego (FAAH) do leczenia lęku, bólu i innych schorzeń
LU92555I2 (fr) Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l&#39;ingrédient actif approuvé est l&#39;Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
ATE304003T1 (de) Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
EP1636182A4 (en) PRODRUGS OF INHIBITORS FROM MITOTIC KINESINE
EP1671957A4 (en) THIADIAZOLINDERIVATE
EA200800065A1 (ru) Аминокислые соли росиглитазона
DE60202669D1 (de) 6-phenylbenzonaphthyidine
WO2005077906A8 (en) Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
WO2003061652A8 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
RU2008108903A (ru) Пентациклический ингибитор киназы
DE602004021854D1 (de) Pharmazeutisches präparat für die mundhöhle
MXPA05011855A (es) 1,2-diarilimidazoles utiles como inhibidores de ciclooxigenasa.
Tavares et al. Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.